Lung disease induced by novel chemotherapeutic agents and biomolecules Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006
The role of somatostatin analogues in combination to antineoplastic agents in the treatment of SCLC patients (preliminary findings) Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020
A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006
Novel anti-angiogenic pharmacotherapy strategies Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005
How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021
Topically applied budesonide and formoterol in combination inhibit rat lung oedema in a synergistic way but counteract the slight systemic effects of each drug alone on body weight gain Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002
Fast, efficient and realistic in vitro delivery of inhaled drugs to pulmonary cells: Application to the proteasome inhibitor bortezomib Source: Annual Congress 2013 –Cutting edge: drug delivery to the airways Year: 2013
A comparison between the toxic side effects of adriamycin, cyclophosphamide, and etoposide (ACE) and carboplatin with etoposide (CbE) in the treatment of small cell lung cancer (SCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003
Lipid-related anti-cancer drug resistance of lung adenocarcinoma cells Source: Virtual Congress 2021 – Biology of lung cancer: preclinical and translational research Year: 2021
The in vitro study of anticancer new-structure compound, Bostrycin(1403C), from marine fungi, as AKT molecule target for lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010
In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agentSource: Annual Congress 2010 - Models of airways disease Year: 2010
The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Pulmonary toxicity with mefloquine Source: Eur Respir J 2001; 18: 890-892 Year: 2001
The experience of overcome of Mcb.tuberculosis resistance to antituberculosis drugs Source: Eur Respir J 2002; 20: Suppl. 38, 613s Year: 2002
Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020
The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo Source: Eur Respir J 2004; 24: Suppl. 48, 344s Year: 2004
Use of tacrolimus, a potent antifibrotic agent, in bleomycin-induced lung fibrosis Source: Eur Respir J 2006; 27: 460-469 Year: 2006
A study of paclitaxel in two dose combinations with carboplatin in the treatment of small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001